Foot-and-mouth disease virus leader proteinase inhibits dsRNA-induced type I interferon transcription by decreasing interferon regulatory factor 3/7 in protein levels

Biochemical and Biophysical Research Communications
Dang WangShaobo Xiao

Abstract

The leader proteinase (L(pro)) of foot-and-mouth disease virus (FMDV) has been identified as an interferon-beta (IFN-beta) antagonist that disrupts the integrity of transcription factor nuclear factor kappaB (NF-kappaB). In this study, we showed that the reduction of double stranded RNA (dsRNA)-induced IFN-alpha1/beta expression caused by L(pro) was also associated with a decrease of interferon regulatory factor 3/7 (IRF-3/7) in protein levels, two critical transcription factors for activation of IFN-alpha/beta. Furthermore, overexpression of L(pro) significantly reduced the transcription of multiple IRF-responsive genes including 2',5'-OAS, ISG54, IP-10, and RANTES. Screening L(pro) mutants indicated that the ability to process eIF-4G of L(pro) is not required for suppressing dsRNA-induced activation of the IFN-alpha1/beta promoter and decreasing IRF-3/7 expression. Taken together, our results demonstrate that, in addition to disrupting NF-kappaB, L(pro) also decreases IRF-3/7 expression to suppress dsRNA-induced type I IFN production, suggesting multiple strategies used by FMDV to counteract the immune response to viral infection.

References

Dec 1, 1985·The Journal of General Virology·B E ClarkeD J Rowlands
Jul 13, 2000·The Journal of Biological Chemistry·R LinJ Hiscott
Sep 14, 2002·The Journal of Biological Chemistry·Nicole FoegerTim Skern
Jan 16, 2003·Virus Research·Peter W MasonBarry Baxt
Feb 3, 2007·Journal of Virology·Paola M BarralVincent R Racaniello
Mar 31, 2007·The Journal of Biological Chemistry·John Hiscott
Sep 21, 2007·Journal of Virology·Teresa de Los SantosMarvin J Grubman
Dec 20, 2007·The Journal of General Virology·Richard E Randall, Stephen Goodbourn
Dec 21, 2007·Genes and Immunity·J AndersenN C Reich

❮ Previous
Next ❯

Citations

Apr 20, 2011·Transboundary and Emerging Diseases·W T GoldeB Charleston
Jan 19, 2016·Antiviral Research·Wenchun FanXiangmin Li
Oct 23, 2015·The Journal of General Virology·Shuo SuShoujun Li
Nov 17, 2010·Developmental and Comparative Immunology·Dang WangShaobo Xiao
Mar 22, 2016·Archives of Virology·Hongxia WuLiandong Qu
Jun 9, 2015·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Jin TianLiandong Qu
Jul 28, 2013·Virology·Maria Teresa Sanchez-AparicioFrancisco Sobrino
Dec 22, 2016·Viruses·Wendy Ullmer, Bert L Semler
Aug 30, 2017·FEBS Letters·Jian Lei, Rolf Hilgenfeld
Jun 30, 2018·PLoS Pathogens·Miguel Rodríguez PulidoMargarita Sáiz
Jul 18, 2014·Journal of Virology·Lisbeth Ramírez-CarvajalTeresa de los Santos
Nov 9, 2018·Journal of Virology·Linda J VisserFrank J M van Kuppeveld
Jan 28, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dan LiHongbing Shu
Sep 9, 2017·Critical Reviews in Microbiology·Puja Kumari, Himanshu Kumar
Jul 15, 2017·Cell Communication and Signaling : CCS·Angela J LowreyGretchen L Bentz
Nov 30, 2018·Frontiers in Microbiology·Gisselle N MedinaTeresa de Los Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.